Clinical Trial Update: An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5% versus latanoprost 0.005% in subjects with glaucoma or oc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Brimonidine tartrate 0.2% / Timolol maleate 0.5% fixed combination (brimonidine tartrate; timolol maleate)
• Latanoprost 0.005% (latanoprost)

Snippet

Sponsor: Allergan | Conditions: Glaucoma, Ocular Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2011-09-21